Mobosetinib (Anvili) belongs to several generations of targeted drugs and its research and development background

Mobocertinib is an oral small molecule tyrosine kinase inhibitor (TKI) that belongs to the third generation of EGFR targeted drugs. It mainly targets epidermal growth factor receptor (EGFR) exon 20 insertion mutation (Exon20 In patients with non-small cell lung cancer (NSCLC) driven by insertion), such mutations have limited efficacy in traditional first- and second-generation EGFR inhibitor treatments. The third-generation design enables mobosetinib to inhibit mutant EGFR while causing relatively little inhibition of wild-type EGFR, thereby improving target selectivity and reducing related side effects.

The development background of mobosetinib stems from in-depth research on EGFR mutation heterogeneity and resistance to targeted therapy. EGFRExon 20Insertion mutations are a relatively rare but clinically challenging type of driver mutation in NSCLC . These patients have poor response to first- and second-generation EGFR inhibitors, and the efficacy of chemotherapy is limited. Innovative targeted drugs are urgently needed. Mobocertinib was developed to fill this clinical gap and provide effective treatment options for EGFR Exon20 mutation-positive patients.

During the research and development process, mobosetinib has undergone multi-stage clinical trials, including I phase and II phase studies, showing its efficacy against < patients with span>EGFRexon20insertion mutationsNSCLC have impressive response and disease control rates. Trial data show that the drug can significantly extend progression-free survival (PFS) and improve symptoms while being well tolerated, bringing new treatment hope to this special population.

In general, as a third-generation EGFR targeting drug, mobosetinib is not only superior to traditional first- and second-generation drugs in terms of targeting selectivity and efficacy, but also by targeting exon 20The insertional mutation is specifically designed to address the clinical needs of patients with this refractory subtype. Its successful development marks another breakthrough in the field of EGFR mutated NSCLC targeted therapy, providing important support for precision medicine.

Reference link:https://www.drugs.com